Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib

Authors

Jianjiao Ni (ORCID: https://orcid.org/0000-0003-3113-2586)
Ruiting Ye
Qing Xia (ORCID: https://orcid.org/0000-0002-0506-9977)
Shengping Wang (ORCID: https://orcid.org/0000-0003-3064-9348)
Shuai Liu (ORCID: https://orcid.org/0000-0001-9909-0664)
Qiao Li (ORCID: https://orcid.org/0000-0002-7472-5333)
Li Chu (ORCID: https://orcid.org/0000-0002-6301-2709)
Xiao Chu (ORCID: https://orcid.org/0000-0002-1630-0388)
Xi Yang (ORCID: https://orcid.org/0000-0002-9843-3925)
Yue Zhou (ORCID: https://orcid.org/0000-0003-4012-4270)
Ya Zeng
Zhengfei Zhu

Institutions

Shanghai Medical College of Fudan University (CN)
Renji Hospital (CN)
Shanghai Chest Hospital (CN)
Fudan University Shanghai Cancer Center (CN)
Shanghai Clinical Research Center (CN)

Publication Details

Journal: Clinical & Experimental Metastasis
Published: 2025-05-29
DOI: https://doi.org/10.1007/s10585-025-10351-4
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Funders

National Natural Science Foundation of China
Chinese Society of Clinical Oncology

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib

Jianjiao Ni, Ruiting Ye, Qing Xia, Shengping Wang et al.

May 29, 2025

Clinical & Experimental Metastasis

Lung Cancer Treatments and Mutations

article

Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib

Jianjiao Ni, Ruiting Ye, Qing Xia, Shengping Wang, Shuai Liu, Qiao Li, Li Chu, Xiao Chu, Xi Yang, Yue Zhou, Ya Zeng, Zhengfei Zhu

May 29, 2025article en

Abstract

No abstract available for this paper.

Clinical & Experimental MetastasisVol. 42(4)

Shanghai Medical College of Fudan University (CN), Renji Hospital (CN), Shanghai Chest Hospital (CN), Fudan University Shanghai Cancer Center (CN), Shanghai Clinical Research Center (CN)

National Natural Science Foundation of China, Chinese Society of Clinical Oncology

Openalex Percentile: Top 80%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib — Jianjiao Ni, Ruiting Ye, et al. · Clinical & Experimental Metastasis (2025) | TGRS Research Map | TGRS